prazepam (centrax) Report issue

Small molecule Approved FDA
ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Prazepam is a benzodiazepine derivative and is indicated to treat symptoms of anxiety. Benzodiazepines are used to treat severe incapacitating symptoms or symptoms leading to an extreme suffering for the patient. Prazepam is believed to stimulate GABA receptors in the ascending reticular activating system. Since GABA is inhibitory, receptor stimulation increases inhibition and blocks both cortical and limbic arousal following stimulation of the brain stem reticular formation. Prazepam is a prodrug for N-desmethyl-diazepam, which is responsible for the therapeutic effects of prazepam. Prazepam was discontinued in USA.   NCATS

Chemistry

  • SMILES: ClC1=CC=C2N(CC3CC3)C(=O)CN=C(C4=CC=CC=C4)C2=C1
  • InChIKey: MWQCHHACWWAQLJ-UHFFFAOYSA-N
  • Mol. Mass: 324.804
  • ALogP: 3.93
  • ChEMBL Molecule:
    prazepam  
More Chemistry

Pharmacology

Alternative names

centrax | demetrin | prazene | prazepam | prazepamum | sedapran | trepidan | verstran | w-4020

Organizations (3)

Research & Development (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (1)


 

Anxiety (approved 1987)

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue